TOPGEAR 试验--化放疗是否不再是胃癌多学科治疗的组成部分？

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-10-21 DOI:10.1038/s41571-024-00960-5

Brian Badgwell

引用次数: 0

摘要

事实证明，与单纯手术相比，辅助放化疗对接受前期胃癌切除术的患者有生存益处。现在，TOPGEAR 试验的数据表明，在标准护理围手术期化疗的基础上增加放疗并不会带来额外的生存获益。我将讨论这对治疗和未来研究的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The TOPGEAR trial — is chemoradiotherapy no longer a component of multidisciplinary care for gastric cancer?

Adjuvant chemoradiotherapy has a proven survival benefit for patients undergoing upfront resection of gastric cancer compared with surgery alone. Now, data from the TOPGEAR trial demonstrate that adding radiotherapy to standard-of-care perioperative chemotherapy offers no additional survival benefit. I discuss the implications for treatment and future research.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.